Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System
30.1.2026 09:30:00 EET | Business Wire | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine.
In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market.
Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinical research. With over 3,000 peer- reviewed and published articles, the company currently has 32 ongoing global clinical study projects enrolling 600+ patients with over 2,000 study visits, treating a wide range of skin types and conditions.
The launch of the Glacē system, together with the upcoming launch of the Matrix and VBeam Pro systems, provides best-in-class treatment solutions for skin health including skin tightening, texture, acne, scars, advanced vascular treatments and overall skin quality.
The Glacē System is a professional facial system designed for high-frequency skin care for medical, wellness and aesthetic providers. Engineered as a comprehensive skin purifying platform, the Glacē system functions both as a standalone facial treatment and as a clinically proven adjunct to energy-based device treatments to support improved skin quality, patient comfort and consistent results. The Glacē system enables a broader segment of practices — spanning the range from beauty-focused to medical aesthetic practices, to offer a modern, repeatable skin health treatment while enhancing combination treatment outcomes for practices using Candela devices.
The Matrix System (currently pending EU MDR clearance) is Candela’s next-generation skin renewal workstation that combines intelligent, outcomes-driven energy delivery with safety-by-design engineering. The multiapplication radiofrequency (RF) platform integrates skin resurfacing, microneedling and noninvasive wrinkle treatment within a single device to address multiple layers of the skin with precision. Powered by Candela’s signature Aesthetic Intelligence technology, the Matrix system is designed to sense, adapt and display tissue impedance in real time, supporting safe, smooth and consistent heating across applications, skin types and depths. This intelligent performance allows providers to deliver reproducible outcomes across all skin types and a wide range of indications, notably skin tightening, acne scarring, textural irregularities and collagen loss.
The Vbeam Pro system, launched in 2025 in the U.S., is the only vascular laser FDA-cleared for use in pediatric patients. It combines an advanced 595 nm pulsed dye laser with a 1064 nm Nd:YAG wavelength to offer unmatched precision, accuracy and treatment versatility. The platform is designed to effectively treat a broad spectrum of skin conditions, including pediatric and adult vascular abnormalities, rosacea, port-wine stains, acne, leg veins, spider veins, scars, benign pigmented lesions, wrinkles, warts, stretch marks, and photoaging.
“Developing innovative products that powerfully enhance skin health and youthfulness is our passion. We are excited to be unveiling the Matrix, Glacē and VBeam Pro systems here,” said Geoffrey Crouse, Chief Executive Officer of Candela. “By launching these major platforms, we are accelerating our ability to serve customers in the fast-evolving European and global market, where patient demand continues to grow, and our scientific and clinically proven treatment solutions continue to uniquely address skin quality, laxity, texture, tone and more.”
As part of this next chapter of innovation, Candela is also unveiling experience-driven customer engagement — pairing scientific exchange with immersive brand experience designed to foster engagement with key opinion leaders, partners and customers, including exclusive clinical and customer experiences held in conjunction with IMCAS.
“As someone whose practices use both the Glacē and Matrix systems, I see these platforms as highly complementary,” said Firas Al-Niaimi, MD, Professor of Laser Dermatology and a Board-Certified Dermatologist with a private practice in London. “Together, they allow us to comprehensively address skin health — including skin laxity, texture and tone — safely with precision and confidence. Candela continues to invest not only in technology, but also in addressing the needs of a broader cross-section of aesthetic practices and their patients in clinically validated ways that meaningfully and positively impact our patient experience.”
Candela will showcase the Glacē, Matrix and VbeamPro Systemsat IMCAS 2026, featuring live product demonstrations, scientific presentations, a dedicated symposium on Epigenetics and Skin Health, and other engagement opportunities with its global clinical community.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260129455611/en/
Contacts
Sarvar Kothavala
VP, Global Advocacy, Professional Education & Strategic Insights
Mobile: +1.415.760.0902
Email: sarvark@candelamedical.com
Elena Yacoub
We. Communications
Office: +1.425.578.1757
Email: eyacoub@wecommunications.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alipay Launches Next-Generation AI Payment Infrastructure, Debuts AI Wallet and Token Pay to Power Agentic Economy26.5.2026 18:20:00 EEST | Press release
Alipay today introduced its full-stack AI payment solution to partners across industries, ranging from AI companies to traditional retailers, and debuted two new services — the world’s first AI Wallet and Token Pay — to support the agentic economy’s rapid growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526337824/en/ Alipay Unveils Next-generation AI Payment Infrastructure This launch extends Alipay's next-generation AI payment infrastructure, building on its consumer-facing product Alipay AI Pay and its business-facing AI payment processing product. “While the essence of commerce remains unchanged in the age of AI, the emergence of AI agents is reshaping everything. Drawing on 22 years of technological expertise and commercial know-how, Alipay is building a new generation of AI payment services to accelerate the growth of the agentic commerce ecosystem,” said Cyril Han, CEO of Ant Group. AI Wallet: Giving Users Vis
Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 202626.5.2026 18:00:00 EEST | Press release
Daiichi Sankyo Europe (DSE) is pleased to announce its extensive scientific presence at the European Atherosclerosis Society (EAS) Congress 2026. The presentation of 15 abstracts, comprising both clinical trial analyses and real-world evidence, underscores the company's sustained investment in cardiovascular health and its mission to care for every heartbeat. The 15-abstract showcase provides a comprehensive look at the role of bempedoic acid in lipid management. This includes post-hoc analyses in collaboration with Esperion Therapeutics from the Phase 3 CLEAR Outcomes trial exploring its impact on stroke and venous thromboembolism (VTE) incidence.5,6 There are also real-world findings from the MILOS registry, including a dedicated sub-analysis investigating the effectiveness of bempedoic acid across various background therapies.1,2,3,4 Results reinforce consistent effectiveness and safety profile of bempedoic acid across various EU countries and regardless of patients’ existing treatm
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 16:15:00 EEST | Press release
OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leading AI providers, including Anthropic, Google, OpenAI, xAI, and DeepSeek, among others. The platform is used by over 8 million global users, including AI-native startups and large enterprises,
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 16:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in markets traditional channels can't reach. Each operates at the center of how games are discovered, adopted, an
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 15:00:00 EEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom